Treatments involving oral or intragastric administration of edaravone

摘要

The present invention is a liquid pharmaceutical composition for use in medical treatment, wherein the liquid pharmaceutical composition comprises a non-conjugated 3-methyl-1-phenyl-2-pyrazolin-5-one (edaravone). Oral or intragastric administration of 10-250 mL of a liquid pharmaceutical composition, which is a monophasic aqueous solution, comprising at least 7% by weight of water and 0.2-9 mg / mL edaravone, wherein treatment results in 30-300 mg edaravone. Liquid pharmaceutical compositions, including administration. [Selection diagram] None